Interleukin-18 [IL-1F4]

The Cytokine Handbook

Volumn , Issue , 2003, Pages 709-733

  Okamura, Haruki ^a   Lotze, Michael T ^b   Tsutsui, Hiroko ^a   Kashiwamura, Shin ichiro ^a   Ueda, Haruyasu ^a   Yoshimoto, Tomohiro ^a   Nakanishi, Kenji ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Molecular Medicine Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0348251995     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012689663-3/50033-8     Document Type: Chapter

References (302)

1. Adachi O., Kawai T., Matsumoto M., et al. Targeted disruption of the MyD88 gene results in loss of IL-1 and IL-18-mediated function. Immunity 1998, 9:143-150.
2. Ahn H.-J., Maruo S., Tomura M., et al. A mechanism underlying synergy between IL-12 and IFNγ-inducing factor in enhanced production of IFN γ. J. Immunol. 1997, 159:2125-2131.
3. Aizawa Y., Akita K., Taniai M., et al. Cloning and expression of interleukin-18 binding protein. FEBS Letters 1999, 445:338-342.
4. Akira S. The role of IL-18 in innate immunity. Curr. Opin. Immunol. 2000, 12:59-63.
5. Akira S., Takeda K., Kaisho T. Toll-like receptor: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680.
6. Akita K., Ohtsuki T., Nukada Y., et al. Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP 1 cells. J. Biol. Chem. 1997, 272:26595-26603.
7. Alleva D.G., Johnson E.B., Lio F.M., et al. Regulation of murine macrophage pro-inflammatory and antiinflammatory cytokines by ligands for peroxisome proliferator-activated receptor-gamma: counter-regulatory activity by IFN-gamma. J. Leukoc. Biol. 2002, 71:677-685.
8. Amo Y., Ohta Y., Hamada Y., Katsuoka K. Serum levels of interleukin-18 are increased in patients with cutaneous T-cell lymphoma and cutaneous natural killer-cell lymphoma. Br. J. Dermatol. 2001, 145:674-676.
9. Balashov K.E., Rottman J.B., Weiner H.L., Hancock W.W. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc. Natl. Acad. Sci. USA 1999, 96:6873-6878.
10. Barbulescu K., Becker C., Schlaak J.F., et al. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J. Immunol. 1998, 160:3642-3647.
11. Bar-Shira A., Rashi-Elkeles S., Zlochover L., et al. ATM-dependent activation of the gene encoding MAP kinase phosphatase 5 by radiomimetic DNA damage. Oncogene 2002, 21:849-855.
12. Baysal B.E., Willett-Brozick J.E., Taschner P.E., et al. A high-resolution integrated map spanning the SDHD gene at 11q23: a 1.1-Mb BAC contig, a partial transcript map and 15 new repeat polymorphisms in a tumoursuppressor region. Eur. J. Hum. Genet. 2001, 9:121-129.
13. Blease K., Kunkel S.L., Hugaboam C.M. IL-18 modulates chronic fungal asthma in a murine model; putative involvement of Toll-like receptor-2. Inflamm. Res. 2001, 50:552-560.
14. Bohn E., Sing A., Zumbihl R., et al. IL-18 (IFNγ-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J. Immunol. 1998, 160:299-307.
15. Born T.L., Thomasson E., Bird T.A., Sims J.E. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J. Biol. Chem. 1998, 273:29445-29450.
16. Born T.L., Morrison L.A., Esteban D.J., et al. A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell responses. J. Immunol. 2000, 164:3246-3254.
17. Bowie A., O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. J. Leukoc. Biol. 2000, 64:508-514.
18. Bras A., Martinez A.C., Baixeras E. B cell receptor cross-linking prevents Fas-induced cell death by inactivating the IL-1 beta-converting enzyme protease and regulating Bcl-2+Bcl-x expression. J. Immunol. 1997, 159:3168-3177.
19. Brieland J.K., Jackson C., Hurst S., et al. Immunomodulatory role of endogenous interleukin-18 in gamma interferon-mediated resolution of replicative Legionella pneumophila lung infection. Infect. Immun. 2000, 168:6567-6573.
20. Brummer E. Human defenses against Cryptococcus neoformans: an update. Mycopathologia 1999, 143:121-125.
21. Cai G., Kastelein R.A., Hunter C.A. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN gamma when combined with IL-18. Eur. J. Immunol. 1999, 29:2658-2665.
22. Cai G., Radzanowski T., Villegas E.N., et al. Identification of STAT4-dependent and independent mechanisms of resistance to Toxoplasma gondii. J. Immunol. 2000, 165:2619-2627.
23. Calderara S., Xing Y., Moss B. Orthopoxvirus IL-18 binding proteins: affinities and antagonist activities. Virology 2001, 279:22-26.
24. Cappellen D., Luong-Nguyen N.H., Bongiovanni S., et al. Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator of Nfkappa B. J. Biol. Chem. 2002, 277:21971-21982.
25. Carson W.E., Dierksheide J.E., Jabbour S., et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-γ production and STAT-mediated signal transduction. Blood 2000, 96:1469-1473.
26. Chan W.L., Pejnovic N., Lee C.A., Al-Ali N.A. Human IL-18 receptor and ST2L are stable and selective markers for the respoective type 1 and type 2 circulating lymphocytes. J. Immunol. 2001, 167:1238-1244.
27. Chang G.Y., Brautigan D.L., Larner J.M. Ionizing radiation activates nuclear protein phosphatase-1 by ATM-dependent dephosphorylation. J. Biol. Chem. 2002, 277:41756-41761.
28. Chikano S., Sawada K., Shimoyama T., et al. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ-dependent manner. Gut 2000, 47:779-786.
29. Cho D., Song H., Kim Y.M., et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res. 2000, 60:2703-2709.
30. Coeshott C., Ohnemus C., Pilyavskaya A., et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1 beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc. Natl. Acad. Sci. USA 1999, 96:6261-6266.
31. Conti B., Jahng J.W., Tinti C., et al. Induction of interferon-γ inducing factor in the adrenal cortex. J. Biol. Chem. 1996, 264:2035-2037.
32. Conti B., Park L.C., Calingasan N.Y., et al. Cultures of astrocytes and microglia expression interleukin 18. Brain Res. Mol. Brain Res. 1999, 67:46-52.
33. Conti B., Sugama S., Kim Y., et al. Modulation of IL-18 production in the adrenal cortex following acute ACTH or chronic corticosterone treatment. Neuroimmunomodulation 2000, 8:1-7.
34. Coughlin C.M., Sakhany K.E., Wysocka M., et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 1998, 101:1441-1452.
35. Daemen M.A., van't Veer C., Wolfs T.G., Buurman W.A. Ischemia reperfusion-induced IFNgamma upregulation: involvement of IL-12 and IL-18. J. Immunol. 1999, 162:5506-5510.
36. Dale M., Nicklin M.J. Interleukin-1 receptor cluster: gene organization of IL1R2, IL1R1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL18R1 (IL-1Rrp) on human chromosome 2q. Genomics 1999, 57:177-179.
37. Dao T., Ohashi K., Kayano T., et al. Interferon-γ inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell. Immunol. 1996, 173:230-235.
38. Dao T., Mehal W.Z., Crispe I.N. IL-18 augments perforin-dependent cytotoxicity of liver NK-T cells. J. Immunol. 1998, 161:2217-2222.
39. Daun J.M., Fenton M.J. Interleukin-1/Toll receptor family members: receptor structure and signal transduction pathways. J. Interferon Cytokine Res. 2000, 20:843-855.
40. Dayer J.M. Interleukin-18, rheumatoid arthritis, and itssue destruction. J. Clin. Invest. 1999, 104:1337-1339.
41. Debets R., Timans J.C., Churakowa S., et al. IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J. Immunol. 2000, 165:4950-4956.
42. Debets R., Timans J.C., Homey B., et al. Two novel IL-1 family members, IL-1δ and IL-1ε, function as an antagonist and agonist of NFκB activation through the arphan IL-1 receptor-related protein 2. J. Immunol. 2001, 167:1440-1446.
43. Dinarello C.A. Biological basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
44. Dinarello C.A. Interleukin-1, interleukin-1 receptor and interleukin-1 receptor antagonist. Int. Rev. Immunol. 1998, 16:457-499.
45. Dinarello C.A., Novick D., Puren A.J., et al. Overview of interleukin-18, more than an interferon-γ inducing factor. J. Leukoc. Biol. 1998, 63:658-664.
46. Dinarello C.A. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw. 2000, 11:483-486.
47. Dinney C.P., Bielenberg D.R., Perrotte P., et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998, 58:808-814.
48. Elhofy A., Bost K.L. Limited interleukin-18 response in salmonella-infected murine macrophages and in salmonella-infected mice. Infect. Immun. 1999, 67:5021-5026.
49. Esposito K., Pontillo A., Ciotola M., et al. Weight loss reduces interleukin-18 levels in obese women. J. Clin. Endocrinol. Metab. 2002, 87:3864-3866.
50. Faggioni R., Cattley R.C., Guo J., et al. IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J. Immunol. 2001, 167:5913-5920.
51. Fantuzzi G., Ku G., Harding M.W., et al. Response to local inflammation of IL-1 beta-converting enzyme deficient mice. J. Immunol. 1997, 158:1818-1824.
52. Fantuzzi G., Dinarello C.A. Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J. Clin. Immunol. 1999, 19:1-11.
53. Fassbender K., Mielke O., Bertsch T., et al. Interferon-gamma-inducing factor (IL-18) and interferon-gamma in inflammatory CNS diseases. Neurology 1999, 53:1104-1106.
54. Fehniger T.A., Shah M.H., Turner M.J., et al. Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J. Immunol. 1999, 162:4511-4520.
55. Fitzgerald K.A., Palsson-McDermott E.M., Bowie A.G., et al. Mal (MyD88-adapter-like) is required for Toll-like receptro-4 signal transduction. Nature 2001, 413:78-83.
56. Fujioka N., Akazawa R., Ohashi K., et al. Interleukin-18 protects mice against acute herpes simplex virus type 1 infection. J. Virol. 1999, 73:2401-2409.
57. Fukao T., Matsuda S., Koyasu S. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFNγ-production by dendritic cells. J. Immunol. 2000, 164:64-71.
58. Fukumoto H., Nishio M., Nishio K., et al. Interferon gamma-inducing factor gene transfection into Lewis lung carcinoma cells reduces tumorigenicity in vivo. Japanese J. Cancer Res. 1997, 88:501-505.
59. Furlan R., Martiono G., Galbiati F., et al. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. 1999, 162:2403-2409.
60. Garcia V.E., Uyemura K., Sieling P.A., et al. IL-18 promotes type 1 cytokine production from Nk cells and T cells in human intracellular infection. J. Immunol. 1999, 162:6114-6121.
61. Gardella S., Andrei C., Poggi A., et al. Control of interleukin-18 secretion by dendritic, dells: role of calcium influxes. FEBS Lett. 2000, 481:245-248.
62. Ghayur T., Banerjee S., Banerjee M.D., et al. Caspase-1 processes IFNγ-inducing factor and regulates LPS-induced IFNγ production. Nature 1997, 386:619-623.
63. Giacomini E., Iona E., Ferroni L., et al. Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates cell responses. J. Immunol. 2001, 166:7033-7041.
64. Gillespie M.T., Horwood N.J. Interleukin-18, Perspectives on the newest interleukin. Cytok. Growth Factor Rev. 1998, 9:109-116.
65. Golab J. Interleukin 18-interferon gamma inducing factor- a novel player in tumour immunotherapy?. Cytokine 2000, 12:332-338.
66. Gordon S. Macrophage-restricted molecules: role in differentiation and activation. Immunol. Lett. (Review) 1999, 65:5-8.
67. Grahames C.B., Michel A.D., Chessell I.P., Humphrey P.P. Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes. Br. J. Pharmacol. 1999, 127:1915-1921.
68. Gu Y., Kida K., Tsutsui H., et al. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme. Science 1997, 275:206-209.
69. Hashimoto W., Osaki T., Okamura H., et al. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apotosis, respectively. J. Immunol. 1999, 163:583-589.
70. Hayashi F., Smith K.D., Ozinsky A., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001, 410:1099-1103.
71. Helby H., Takeda K., Akira S., Grencis R.K. Interleukin (IL)-18 promotes the development of chronic gastrointestinal helminth infection by downregulating IL-13. J. Exp. Med. 2001, 194:353-364.
72. Hemby H., Grencis R.K. IL-18 regulates intestinal mastocytosis and Th2 cytokine production independently of IFN-gamma during Trichinella spiralis infection. J. Immunol. 2002, 169:2553-2560.
73. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
74. Henneke P., Golenbock D.T. TIRAP: how Toll receptors fraternize. Nat. Immunol. 2001, 2:828-830.
75. Heuer J.G., Tuchker-McClung C., Hock R.A. Neuroblastoma cells expressing mature IL-18, but not proIL-18, induce a strong and immediate antitumor immune response. J. Immunotherapy 1999, 22:324-335.
76. Holland E.C., Varmus H.E. Basic fibroblast growth factor induces cell migration and proliferation after glia specific gene transfer in mice. Proc. Natl. Acad. Sci. USA 1998, 95:1218-1223.
77. Horng T., Barton G.M., Medzhitov R. TIRAP: an adapter modecule in the Toll signalling pathway. Nat. Immunol. 2001, 2:835.
78. Horwood N.J., Udagawa N., Elliott J., et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J. Clin. Invest. 1998, 101:595-603.
79. Horwood N.J., Elliott J., Martin T.J., Gillespie M.T. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 2001, 166:4915-4921.
80. Hoshino K., Tsutsui H., Kawai T., et al. Generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor. J. Immunol. 1999, 162:5041-5044.
81. Hoshino K., Takeuchi O., Kawai T., et al. Toll-like receptor 4 (TLR4)-deficient mice are lyporesponsive to lipopolysaccharide: Evidence for TLR4 as lps gene product. J. Immunol. 1999, 162:3749-3752.
82. Hoshino T., Wiltrout R.H., Young H.A. IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. 1999, 162:5070-5077.
83. Hoshino T., Yagita H., Ortldo R.H., Young H.A. In vivo administration of IL-18 can induce IgE production through TH2 cytokine induction and up-regulation of CD40 ligand (CD154) expression on CD4+T cells. Eur. J. Immunol. 2000, 30:1998-2006.
84. Hoshino T., Kawase Y., Okamoto M., et al. IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function. J. Immunol. 2001, 166:7014-7018.
85. Humphreys B.D., Dubyak G.R. Modulation of P2X7 nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes. J. Leukoc. Biol. 1998, 64:265-273.
86. Hunter C.A., Timans J., Pisacane P., et al. Comparison of the effects of interleukin-1α, interleukin-1β and interferon-γ-inducing factor on the production of interferon-γ by natural killer cells. Eur. J. Immunol. 1997, 27:2787-2792.
87. Hyodo Y., Matsui K., Hayashi N., et al. Interleukin 18 upregulates perforin-mediated NK activity without increasing perforin mRNA expression by binding to constitutively expressed IL-18R. J. Immunol. 1999, 162:1662-1668.
88. Im S.H., Barchan D., Maiti P.K., et al. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18. FASEB J. 2001, 15:2140-2148.
89. Iwahashi H., Itoh N., Yamagata K., et al. Molecular mechanisms of pancreatic beta-cell destruction in autoimmune diabetes, potential targets for, preventive therapy. Cytokines Cell Mol. Ther. 1998, 4:45-51.
90. Iwasaki T., Yamashita K., Tsujimura T., et al. Interleukin-18 inhibits osteolytic bone metastasis by human lung cancer cells possibly through suppression of osteoclastic bone-resorption in nude mice. J. Immunother. 2002, 25(Suppl. 1):S52-S60.
91. Jander S., Stoll G. Differential induction of interleukin-12, interleukin-18 and interleukin-1 beta converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. J. Neuroimmunol. 1998, 91:93-99.
92. Jander S., Stoll G. Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 2001, 114:253-258.
93. Jander S., Stoll G. Increased serum levels of the interferon-gamma-inducing cytokine interleukin-18 in myasthenia gravis. Neurology 2002, 59:287-289.
94. John B., Rajagopal D., Pashine A., et al. Role of IL-12-independent and IL-12-dependent pathways in regulating generation of the IFN-gamma component of T cell responses to Salmonella typhimurium. J. Immunol. 2002, 169:2545-2552.
95. Joshi V.D., Kalvakolanu D.V., Hasday J.D., et al. IL-18 levels and the outcome of innate immune response to lipopolysaccharide: importance of a positive feedback, loop with caspase-1 in IL-18 expression. J. Immunol. 2002, 169:2536-2544.
96. Ju D.W., Tao Q., Lou G., et al. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates. Cancer Res. 2001, 61:3735-3740.
97. Kaanakaray P., Ngo K., Wu Y., et al. Defective Interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice. J. Exp. Med. 1999, 189:1129-1138.
98. Kalina U., Kauschat D., Koyama N., et al. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. J. Immunol. 2000, 165:1307-1313.
99. Kalina U., Kauschat D., Koyama N., et al. IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-γ production by the stress kinase p38 and by the extracellular regulated kinases p44erk-1 and p42erk-21. J. Immunol. 2000, 165:1307-1313.
100. Kampfer H., Kalina U., Muhl H., et al. Counterregulation of interleukin-18 mRNA and protein expression during cutaneous wound repair in mice. J. Invest. Dermatol. 1999, 113:369-374.
101. Kampfer H., Paulukat J., Muhl H., et al. Lack of interferon-gamma production despite the presence of interleukin-18 during cutaneous wound healing. Mol. Med. 2000, 6:1016-1027.
102. Kanai T., Watanabe M., Okazawa A., et al. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterol. 2000, 119:1514-1523.
103. Kanai T., Watanabe M., Okazawa A., et al. Interleukin-18 and Crohn's disease. Digestion 2001, 63:37-42.
104. Karni A., Koldzic D.N., Bharanidharan P., et al. IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD49-CD40 lig-and interactions. J. Neuroimmunol. 2002, 125:134-140.
105. Kawabata T., Ichikura T., Majima T., et al. Preoperative serum interleukin-18 level as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 2001, 92:2050-2055.
106. Kawai T., Adachi O., Ogawa T., et al. Umesponsiveness of MyD88-deficient mice to endotoxin. Immunity 1999, 11:115-122.
107. Kawaguchi Y., Terajima H., Harigai M., et al. Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease. Arthritis Rheum. 2001, 44:1716-1717.
108. Kawakami K., Qureshi M.H., Zhang T., et al. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFNγ production. J. Immunol. 1997, 159:5528-5534.
109. Kawakami K., Koguchi Y., Qureshi M.H., et al. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-g production by NK cells. J. Immunol. 2000, 165:941-947.
110. Kawashima M., Yamamura M., Taniai M., et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum. 2001, 44:550-560.
111. Kim Y.M., Talanian R.V., Li J., Billiar T.R. Nitric oxide prevents IL-1β and IFNγ-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1β converting enzyme). J. Immunol. 1998, 161:4122-4128.
112. Kim Y.M., Kang H.S., Paik S.G., et al. Roles of IFN consensus sequence binding protein and PU.1 in regulating IL-18 gene expression. J. Immunol. 1999, 163:2000-2007.
113. Kim S-H., Eisenstein M., Reznikov L., et al. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. USA 2000, 97:1190-1195.
114. Kim S.H., Reznikov L.L., Stuyt R.J.L., et al. Functional reconstitution and regulation of IL-18 activity by the IL-18Rβ chain. J. Immunol. 2001, 166:148-154.
115. Kobashi K., Iwagaki H., Yoshino T., et al. Downregulation of IL-18 receptor in cancer patients: its clinical significance. Anticancer Res. 2001, 21:3285-3293.
116. Kobayashi K., Nakata N., et al. Decreased expression of cytokines that induce type 1 helper T cell/interferon-gamma responses in genetically susceptible mice infected with Mycobacterium avium. Clin. Immunol. Immunopathol. 1997, 85:112-116.
117. Kobayashi K., Kai M., Gidoh M., et al. The possible role of interleukin (IL)-12 and interferon-gamma-inducing factor/IL-18 in protection against experimental Mycobacterium leprae infection in mice. Clin. Immunol. Immunopathol. 1998, 88:226-231.
118. Kohno K., Kataoka J., Ohtsuki T., et al. IFNγ-Inducing factor (IGIF) is a constimulatory factor on the activation of TH1 but not TH2 cells and exerts its effect independently of IL-12. J. Immunol. 1997, 158:1541-1550.
119. Kohyama M., Saijyo K., Hayashida M., et al. Direct activation of human CD8 cytotoxic T lymphocytes by interleukin-18. Jpn J. Cancer Res. 1998, 89:1041-1046.
120. Koizumi H., Sato-Matsumura K.C., Nakamura H., et al. Distribution of IL-18 and IL-18-receptor in human skin: various forms of IL-18 are produced in keratinocytes. Arch. Dermatol. Res. 2001, 293:325-333.
121. Kojima H., Takeuchi M., Ohta T., et al. Interleukin-18 activates the IRAK-TRAF6 pathway in mouse EL-4 cells. Biochem. Biophys. Res. Commun. 1998, 244:183-186.
122. Kolkowski E.C., Reth P., Pelusa F., et al. TH1 predominance and perforin expression in minor salivary glands from patients with primary Sjogren's syndrome. J. Autoimmun. 1999, 13:155-162.
123. Konishi H., Tsutsui H., Murakami T., et al. IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proc. Natl. Acad. Sci. USA 2002, 99:11340-11345.
124. Kumano K., Nakano A., Nakajima H., et al. Interleukin-18 enhances antigen-induced eosinophil recruitment into the mouse airway. Am. J. Respir. Crit. Care Med. 1999, 160:873-878.
125. Kumar S., Hanning C.R., Brigham-Burke M.R., et al. Interleukin-1F7B (IL-1H4/IL-1F7) is processes by caspase-1 and mature IL-1F7B binds to the IL-18 receptor but does not induce IFN-gamma production. Cytokine 2002, 18:61-71.
126. Kunikata T., Torigoe K., Usio S., et al. Constitutive and induced IL-18 receptor expression by various peripheral blood Cell subsets as determined by anti-HIL-18R monoclonal antibody. Cell Immunol. 1998, 189:135-143.
127. Lauwerys B.R., Renauld J.C., Houssiau F.A. Inhibition of in vitro immunoglobulin production by IL-12 in murine chronic graft-vs.-host disease synergism with IL-18. Eur. J. Immunol. 1998, 28:2017-2024.
128. Lawless V.A., Zhang S., Ones O.N., et al. Stat4 regulates multiple components of IFN-γ-inducing signaling pathways. J. Immunol. 2000, 165:6803-6808.
129. Lebel-Binay S., Berger A., Zinzindohoue F., et al. Interleukin-18: biological properties and clinical implications. Eur. Cytokine Netw. 2000, 11:15-26.
130. Lee S-J., Cho Y-S., Cho M-C., et al. Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-γ production in human peripheral blood mononuclear and NK cells. J. Immunol. 2001, 167:497-504.
131. Leite-de-Moraes M.C., Hameg A., et al. IL-18 enhances IL-4 production by ligand-activated NKT lymphocytes: a pro-TH2 effect of IL-18 exerted through NKT cells. J. Immunol. 2001, 166:945-951.
132. Leung B.P., McInnes I.B., Esfandiari E., et al. Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis. J. Immunol. 2000, 164:6495-6502.
133. Leung B.P., Culshaw S., Gracie J.A., et al. A role for IL-18 in neutrohil activation. J. Immunol. 2001, 167:2879-2886.
134. Lissoni P., Brivio F., Rovelli F., et al. Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J. Biol. Regul. Homeost. Agents 2000, 14:275-277.
135. Liu Y., Huang H., Saxena A., Xiang J. Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther. 2002, 9:533-542.
136. Losy J., Niezgoda A. IL-18 in patients with multiple sclerosis. Acta Neurol. Scand. 2001, 104:171-173.
137. MacKenzie A., Wilson H.L., Kiss-Toth E., et al. Rapid secretion of interleukin-1beta by microvesicle shedding. Immunity 2001, 15:825-835.
138. Makiishi-Shimobayashi C., Tsujimura T., Iwasaki T., et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem. Biophys. Res. Commun. 2001, 281:361-366.
139. Mallat Z., Corbaz A., Scoazec A., et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001, 104:1598-1603.
140. Mastroeni P., Clare S., Khan S., et al. Interleukin 18 contributes to host resistance and gamma interferon production in mice infected with virulent Salmonella typhimurium. Infect. Immun. 1999, 67:478-483.
141. Mathiak G., Neville L.F., Grass G., et al. Chemokines and interleukin-18 are up-regulated in bronchoalveolar lavage fluid but not in serum of septic surgical ICU patients. Shock 2001, 15:176-180.
142. Matsumoto S., Tuji-Takayama K., Aizawa Y., et al. Interleukin-18 activates NF-kB in murine T helper typel cells. Biochem. Biophys. Res. Commun. 1997, 234:454-457.
143. Matsumoto K., Kanmatsuse K. Interleukin-18 and interleukin-12 synergize to stimulate the production of vascular permeability factor by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome. Nephron. 2001, 85:127-133.
144. McInnes I.B., Gracie J.A., Leung B.P., et al. Interleukin 18; a pleiotropic participant in chronic inflammation. Immunol. Today 2000, 21:312-315.
145. Medzhitov R., Preston-Hurbert P., Janeway C.A. Innate immunity: the virtues of a nonclonal system of recognition. Cell 1998, 91:295-298.
146. Mee J.B., Alam Y., Groves R.W. Human keratinocytes constitutively produce but do not process interleukin-18. Br. J. Dermatol. 2000, 143:330-336.
147. Mehta V.B., Hart J., Wewers M.D. ATP-stimulated release of interleukin (IL)-1β and IL-18 requires priming by lipopolysaccharide and is independent of caspase-1 cleavage. J. Biol. Chem. 2001, 276:3820-3826.
148. Melnikov V.Y., Ecder T., Fantuzzi G., et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J. Clin. Invest. 2001, 107:1145-1152.
149. Mendoza L., Carrascal T., De Luka M., et al. Hydrogen peroxide mediates vascular cell adhesion molecule-1 expression from interleukin-18-activated hepatic sinusoidal enndothelium: Implications for ciruculating cancer cell arrest in the murine liver. Hepatology 2001, 34:298-310.
150. Meyer zum Büschenfelde C., Cramer S., Trumpfheller C., et al. Trypanosoma cruzi induces strong IL-12 and IL-18 gene expression in vivo: correlation with interferon-gamma (IFNgamma) production. Clin Exp. Immunol. 1997, 110:378-385.
151. Micallef M.J., Yoshida K., Kawai S., et al. In vivo antitumor effects of murine interferon-gamma-inducing factor interleukin-18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 1997, 43:361-367.
152. Micallef M.J., Tanimoto T., Kohno K., et al. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Cancer Res. 1997, 57:4557-4563.
153. Micallef M.J., Tanimoto T., Torigoe K., et al. Simultaneous exposure to interleukin-18 and interleukin-10 in vitro synergistically augments murine spleen natural killer cell activity. Cancer Immunol. Immunother. 1999, 48:109-117.
154. Minagawa K., Tsuji Y., Ueda H., et al. Possible correlation between high levels of IL-18 in the cord blood of pre-term infants and neonatal development of periventricular leukomalacia and cerebral plasy. Cytokine 2002, 17:164-170.
155. Miwa K., Asano M., Horai R., et al. Caspase-1 independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nature Med. 1998, 4:1287-1292.
156. Miyauchi S., Mutsuura B., Onji M. Increased levels of serum interleukin-18 in Graves' disease. Thyroid 2000, 10:815-819.
157. Moller B., Kessler U., Rehart S., et al. Expression of interleukin-18 receptor in fibroblast-like synoviocytes. Arthritis Res. 2002, 4:139-144.
158. Monteforte G.M., Takeda K., Rodrigues-Sosa M., et al. Genetically resistant mice lacking IL-18 gene develop TH1 response and control cutaneous Leishmania major infection. J. Immunol. 2000, 164:5890-5893.
159. Monteleone G., Trapasso F., Parrello T., et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J. Immunol. 1999, 163:143-147.
160. Munder M., Mollo M., Eichmann K., Modolell M. Murine macrophages secrete interferon γ upon combinend stimulation with interleukin (IL)-12 and IL-18: A novel pathway of autocrine macrophage activation. J. Exp. Med. 1998, 187:2103-2108.
161. Murata Y., Amao M., Yoneda J., Hamuro J. Intracellular thiol redox status of macrophages directs the Th1 skewing in thioredoxin transgenic mice during aging. Mol. Immunol. 2002, 38:747-757.
162. Muzio M., Ni J., Feng P., Dixit M.V. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal meditators of IL-1 signaling. Science 1997, 278:1612-1615.
163. Nagai H., Hara I., Horikawa T., et al. Gene transfer of secreted-type modified interleukin-18 gene to B16F10 melanoma cells suppresses in vivo tumor growth through inhibition of tumor vessel formation. J. Invest Dermatol. 2002, 119:541-548.
164. Naik S.M., Cannon G., Burbach G.J., et al. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J. Invest. Dermatol. 1999, 113:766-772.
165. Naito Y., Tsujino T., Fujioka Y., et al. Increased circulating interleukin-18 in patients with congestive heart failure. Heart 2002, 88:296-297.
166. Nakahira M., Tomura M., Iwasaki M., et al. An absolute requirement for STAT4 and a role for IFN-γ as an amplifying factor in IL-12 induction of the functional IL-18 receptor complex. J. Immunol. 2001, 167:1306-1312.
167. Nakamura S., Otani T., Ijiri Y., et al. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12. J. Immunol. 2000, 164:3330-3336.
168. Nakamura S., Otani T., Okura R., et al. Expression and responsiveness of human interleukin-18 receptor (IL-18R) on hematopoietic cell lines. Leukemia 2000, 14:1052-1059.
169. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 is a unique cytokine that stimulates both TH1 and TH2 responses dependeing on its cytokine milieu. Cytokine and Growth Factor Rev. 2001, 12:53-72.
170. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both TH1 and TH2 responses. Annu. Rev. Immunol. 2001, 19:423-474.
171. Nakata A., Tsujimura T., Sugihara A., et al. Inhibition by interleukin-18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res. 1999, 19:4131-4138.
172. Neighbors M., Xu X., Barrat F., et al. A Critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon γ production. J. Exp. Med. 2001, 194:343-354.
173. Neumann D., Del Giudice E., Ciaramella A., et al. Lymphocytes from autoimmune MRL lpr/lpr mice are hyper-responsive to IL-18 and overexpress the IL-18 receptor accessory chain. J. Immunol. 2001, 166:3757-3762.
174. Nicoletti F., Conget I., Di Marco R., et al. Serum levels of the interferon-γ-inducing cytokine interleukin-18 are increased in individuals at high risk of developing type I diabetes. Diabetologia 2001, 44:309-311.
175. Nicoletti F., Di Marco R., Mangano K., et al. Increased serum levels of interlukin-18 in patients with multiple sclerosis. Neurology 2001, 24:342-344.
176. Nolan K.F.D., Greaves D.R., Waldmann H. The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci. Genomics 1998, 51:161-163.
177. Novick D., Kim S-H., Fantuzzi G., et al. Interleukin-18 binding protein: a novel modulator of the TH1 cytokine response. Immunity 1999, 10:127-136.
178. Ohta Y., Hamada Y., Katsuoka K. Expression of IL-18 in psoriasis. Arch. Dermatol. Res. 2001, 293:334-342.
179. Ohkusu K., Yoshimoto T., Takeda K., et al. Potentiality of interleukin-18 as a useful reagent for treatment and prevention of Leishmania major infection. Infect. Immun. 2000, 68:2449-2456.
180. Okamoto I., Kohno K., Tanimoto T., et al. Development of CD8+ effector T cells is differentially regulated by IL-18 and IL-12. J. Immunol. 1999, 162:3202-3211.
181. Okamura H., Tsutsui H., Komatsu T., et al. Cloning of a new cytokine that induces IFNγ production by T cells. Nature 1995, 378:88.
182. Okamura H., Tsutsui H., Kashiwamura S., et al. Interleukin-18, a novel cytokine that augments both innate and acquired immunity. Adv. Immunol. 1998, 70:281-312.
183. Okano F., Yamada K. Canine interleukin-18 induces apoptosis and enhances Fas ligand mRNA expression in a canine carcinoma cell line. Anticancer Res. 2000, 20:3411-3415.
184. Olee T., Hashimoto S., Quach J., Lotz M. IL-18 is produced by articular chondrocytes and induces proin-flammatory and catabolic responses. J. Immunol. 1999, 162:1096-1100.
185. O'Neill L.A., Dinarello C.A. The IL-1 receptor/toll-like receptor superfamily: critical receptors for inflammation and host defense. Immunol. Today 2000, 21:206-209.
186. Osaki T., Peron J.M., Cai Q., et al. IFN gammainducing factor/IL-18 administration mediates IFNgamma-and IL-12-independent antitumor effects. J. Immunol. 1998, 160:1742-1749.
187. Pan G., Risser P., Mao W., et al. IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp. Cytokine 2001, 7(13):1-7.
188. Park H., Byun D., Kim T.S., et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett. 2001, 79:215-219.
189. Parnet P., Garka K.E., Bonnert T.P., et al. IL-1Rrp is a novel receptor-like molecule simular to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol. Chem. 1996, 271:3967-3970.
190. Paulukat J., Bosmann M., Nold M., et al. Expression and release of IL-18 binding protein in response to IFN-gamma. J. Immunol. 2001, 167:7038-7043.
191. Perregaux D.G., McNiff P., Laliberte R., et al. ATP acts as an agonist to promote stimulus-induced secretion of IL-1β and IL-18 in human blood. J. Immunol. 2000, 165:4615-4623.
192. Pien G.C., Satoskar A.R., Takeda K., et al. Selective IL-18 requirements for induction of compartmental IFN-γ responses during viral infection. J. Immunol. 2000, 165:4787-4791.
193. Pirhonen J., Sareneva T., Kurimoto M., et al. Virus infection activates IL-1 beta and IL-18 production in human macrophages by a caspase-1-dependent pathway. J. Immunol. 1999, 162:7322-7329.
194. Pizarro T.T., Michie M.H., Bentz M., et al. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosal cells. J. Immunol. 1999, 162:6829-6835.
195. Prinz M., Hanisch U.K. Murine microglial cells produce and respond to interleukin-18. J. Neurochem. 1999, 72:2215-2218.
196. Puren A.J., Fantuzzl G., Gu Y., et al. Interleukin-18 (IFNγ-inducing factor induces IL-8 and IL-1β via TNFα production from non-CD14+ human blood mononuclear cells. J. Clin. Invest. 1998, 101:711-721.
197. Puren A.J., Razeghi P., Fantuzzi G., Dinarello C.A. Interleukin-18 enhances lipopolysaccharide-induced interferon-gamma production in human whole blood cultures. J. Infect. Dis. 1998, 178:1830-1834.
198. Puren A.J., Fantuzzi G., Dinarello C.A. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1 beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc. Natl. Acad. Sci. USA 1999, 96:2256-2261.
199. Raes G., De Baetselier P., Noel W., et al. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J. Leukoc. Biol. 2002, 71:597-602.
200. Reddy P., Teshima T., Kukuruga M., et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 2001, 194:1433-1440.
201. Reznikov L.L., Kim S-H., Westcott J.Y., et al. IL-18 binding protein increases spontaneous and IL-1-induced prostaglandin production via inhibition of IFN-γ. Proc. Natl. Acad. Sci. USA. 2000, 97:2174-2179.
202. Ricote M., Welch J.S., Glass C.K. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm. Res. 2000, 54:275-280.
203. Robak E., Wozniacka A., Sysa-Jedrzejowska A., et al. Circulating angiogenesis inhibitor endostatin and positive endothelial growth regulators in patients with systemic lupus erythematosus. Lupus 2002, 11:348-355.
204. Robinson D., Shibuya K., Mui A., et al. IGIF does not drive TH1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity 1997, 7:571-581.
205. Rothe H., Jenkins N.A., Copeland N.G., Kolb H. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF which is located near Idd2. J. Clin. Invest. 1997, 99:469-474.
206. Rothe H., Hibino T., Itoh Y., et al. Systemic production of interferon-gamma inducing factor (IGIF) versus local IFN gamma expression involved in the development of TH1 insulitis in NOD mice. J. Autoimmun. 1997, 10:251-256.
207. Rothe H., Hausumann A., Casteels K., et al. IL-18 inhibits diabetes development in nonobese diabetic mice by couterregulation of TH1-dependent destructive insulitis. J. Immunol. 1999, 163:1230-1236.
208. Rothe H., Ito Y., Kolb H. Disease resistant, NOD-related strains reveal checkpoints of immunoregulation in the pancreas. J. Mol. Med. 2001, 79:190-197.
209. Saha N., Moldovan F., Tardif G., et al. Interleukin-1 beta-converting enzyme caspase-1 in human osteoarthritic tissues, localization and role in the maturation of interleukin-1 beta and interleukin-18. Arthritis Rheum. 1999, 42:1577-1587.
210. Sakao Y., Takeda K., Tsutsui H., et al. IL-18-deficient mice are resistant to endotoxin-induced liver injury but highly susceptible to endotoxin shock. Int. Immunol. 1999, 11:471-480.
211. Sareneva T., Julkunen I., Matikainen S. IFN-γ and IL-12 induce IL-18 receptro gene expression in human NK and T cells. J. Immunol. 2000, 165:1933-1938.
212. Schindler H., Lutz M.B., Rollinghoff M., Bogdan C. The production of IFN-γ by iL-12/IL-18-activated macrophages requires STAT4 signaling and is inhibited by IL-4. J. Immunol. 2001, 166:3075-3082.
213. Schönbeck U., Mach F., Libby P. Generation of biologically active IL-1β by matrix metalloproteinases, a novel caspase-1-independent pathway of IL-1β processing. J. Immunol. 1998, 161:3340-3346.
214. Seki E., Tsutsui H., Nakano H., et al. LPS-induced IL-18 secretion from murine Kupffer cells independently of MyD88 that is critically involved in induction of production of IL-12 and IL-1β. J. Immunol. 2001, 166:2651-2657.
215. Setsuda J., Teruya-Feldstein J., Harris N.L., et al. Interleukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am. J. Pathol. 1999, 155:257-265.
216. Shao H., Woon M.D., Nakamura S., et al. Requirement of B7-mediated costimulation in the induction of experimental autoimmune anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2001, 42:2016-2021.
217. Shapiro L., Puren A.J., Barton H.A., et al. Interleukin 18 stimulates HIV type 1 in monocytic cells. Proc. Natl. Acad. Sci. USA 1998, 95:12550-12555.
218. Shi F-D., Takeda K., Akira S., et al. IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-γ by NK cells. J. Immunol. 2000, 165:3099-3104.
219. Shigehara K., Shijubo N., Ohmichi M., et al. Increased levels of interleukin-18 in patients with pulmonary sarcoidosis. Am. J. Respr. Crit. Care Med. 2000, 162:1979-1982.
220. Shigehara K., Shifubo N., Ohmichi M., et al. IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J. Immunol. 2001, 166:642-649.
221. Sica A., Dorman L., Viggiano V., et al. Interaction of NFκB and NFAT with the Interferon-γ promoter. J. Biol. Chem. 1997, 272:30412-30420.
222. Sidell N., Han S.W., Parthasarathy S. Regulation and modulation of abnormal immune responses in endometriosis. Ann. NY Acad. Sci. 2002, 955:159-173. discusion 199-200.
223. Sidell N., Han S.W., Parthasarathy S. Regulation and modulation of abnormal immune responses in endometriosis. Ann. NY Acad. Sci. 2002, 955:396-406. (Review).
224. Sims J.E., Nicklin M.J., Bazan J.F., et al. A new nomenclature for IL-1-family genes. Trends Immunol. 2001, 22:536-537.
225. Sivakumar P.V., Westrich G.M., Kanaly S., et al. Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage. Gut 2002, 50:812-820.
226. Smeltz R.B., Chen J., Gu-Li J., Shevach E.M. Regulation of interleukin (IL)-18 receptor α chain expression on CD4+ T cells during T helper (Th) 1/TH2 differentiation: Critical down regulatory role of IL-4. J. Exp. Med. 2001, 194:143-153.
227. Smith V.P., Bryant N.A., Alcami A. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J. Gen. Virol. 2000, 5:1223-1230.
228. Son Y.I., Dallal R.M., Mailliard R.B., et al. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res 2001, 61(3):884-888.
229. Stober D., Schirmbeck R., Reinmann J. IL-12/IL-18-dependent IFNγ release by murine dendritic cells. J. Immunol. 2001, 167:957-965.
230. Stoll S., Müller G., Kurimoto M., et al. Production of IL-18 (IFNγ-inducing factor) messenger RNA and functional protein by murine keratinocytes. J. Immunol. 1997, 159:298-302.
231. Stoll S., Jonuleit H., Schmitt E., et al. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC), DC-derived IL-18 enhances IL-12-dependent TH1 development. Eur. J. Immunol. 1998, 28:3231-3239.
232. Sugama S., Kim Y., Baker H., et al. Tissue-specific expression of rat IL-18 gene and response to adrenocorticotropic ormone treatment. J. Immunol. 2000, 165:6287-6292.
233. Sugawara I., Yamada H., Kaneko H., et al. Role of interleukin-18 (IL-18) in mycobacterial infection in IL-18-gene-disrupted mice. Infect. Immun. 1999, 67:2585-2589.
234. Sugawara S., Uehara A., Nochi T., et al. Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells. J. Immunol. 2001, 167:6568-6575.
235. Sugaya M., Nakamura K., Tamaki K. Interleukins 18 and 12 synergistically upregulate interferon-gamma production by murine dendritic epidermal T cells. J. Invest. Dermatol. 1999, 113:350-354.
236. Suk K., Yeou Kim S., Kim H. Regulation of IL-18 production by IFN γ and PGE2 in mouse microglial cells: involvement of NFκB pathway in the regulatory processes. Immunol. Lett. 2001, 77:79-85.
237. Swantek J.L., Tsen M.F., Cobb M.H., Thomas J.A. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J. Immunol. 2000, 164:4301-4306.
238. Takada H., Ohga S., Mizuno Y., et al. Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis; a novel marker of disease activity. Br. J. Haematol. 1999, 106:182-189.
239. Takeda K., Tsutsui H., Yoshimoto T., et al. Defective NK cell activity and TH1 response in IL-18-deficient mice. Immunity 1998, 8:383-390.
240. Takeuchi M., Nishizaki Y., Sano O., et al. Immunohistochemical and immuno-electron-microscopic detection of interferon-γ inducing factor (interleukin-18) in mouse intestinal epithelial cells. Cell Tissue Res. 1997, 289:499-503.
241. Takeuchi O., Hoshino K., Kawai T., et al. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 1999, 11:443-451.
242. Takeuchi O., Kaufmann A., Grote K., et al. Preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activaing lipopeptide-2 activates immune cells through a Toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol. 2000, 164:554-557.
243. Takeuchi O., Takeda K., Hoshino K., et al. Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int. Immunol. 2000, 12:113-117.
244. Tan J., Crucian B.E., Chang A.E., et al. Interferon-gamma-inducing factor elicits antitumor immunity in association with interferon-gamma production. J. Immunother. 1998, 21:48-55.
245. Tanaka-Kataoka M., Kunikata T., Takayama S., et al. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine 1999, 11:593-599.
246. Tanaka T., Tsutsui H., Yoshimoto T., et al. Interleukin-18 is elevated in the sera from patients with atopic dermatitis and from atopic dermatitis model mice, NC/Nga. Int. Arch. Allergy Immunol. 2001, 125:236-240.
247. Taylor S.L., Renshaw B.R., Garka K.E., et al. Genomic organization of the interleukin-1 locus. Genomics 2002, 79:726-733.
248. Tominaga K., Yoshimoto T., Torigoe K., et al. IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells. Int. Immunol. 2000, 12:151-160.
249. Tomura M., Maruo S., Mu J., et al. Differential capacities of CD4+, CD8+, and CD4+ CD8+ T cell subsets to express IL-18 receptor and produce IFN gamma in response to IL-18. J. Immunol. 1998, 160:3759-3765.
250. Tomura M., Zhou X.Y., Maruo S., et al. A critical role for IL-18 in the proliferation and activation of NK1.1+ CD3+ cells. J. Immunol. 1998, 160:4738-4746.
251. Tone M., Thompson S.A.J., Tone Y., et al. Regulation of IL-18 (IFNγ-inducing factor) gene expression. J. Immunol. 1997, 159:6156-6163.
252. Torigoe K., Ushio S., Okura T., et al. Purification and characterization of human interleukin-18 receptor. J. Biol. Chem. 1997, 272:25737-25742.
253. Tough D.F., Zhang X., Sprent J. An IFN-γ-dependent pathway controls stimulation of memory phenotype CD8+ T cells turn over in vivo by IL-12, IL-18, and IFN-γ. J. Immunol. 2001, 166:6007-6011.
254. Tovey M.G., Meritet J.F., Guymarho J., Maury C. Mucosal cytokine therapy: marked antiviral and antitumor activity. J. Interf. Cytok. Res. 1999, 19:911-921.
255. Tsuji-Takayama K., Matsumoto S., Koide K., et al. Interleukin-18 induces activation and association of p56(lck) and MAPK in a murine TH1 clone. Biochem. Biophys. Res. Commun. 1997, 237:126-130.
256. Tsuji-Takayama K., Aizawa Y., Okamoto I., et al. Interleukin-18 induces interferon-gamma production through NF-kappaB and NFAT activation in murin T helper type 1 cells. Cell. Immunol. 1999, 196:41-50.
257. Tsuji Y., Tamaoki T.H., Hasegawa A., et al. Expression of interleukin-18 and its receptor in mouse ovary. Am. J. Reprod. Immunol. 2001, 46:349-357.
258. Tsutsui H., Nakanishi K., Matsui K., et al. IFN gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 1996, 157:3967-3973.
259. Tsutsui H., Matsui K., Kawada N., et al. IL-18 accounts for both TNF-α-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J. Immunol. 1997, 159:3961-3967.
260. Tsutsui H., Kayagaki N., Kuida K., et al. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity 1999, 11:359-367.
261. Tsutsui H., Matsui K., Okamura H., Nakanishi K. Pathophysiological roles of interleukin-18 for inflammatory liver diseases. Immunol. Rev. 2000, 174:192-209.
262. Udagawa N., Horwood N.J., Elliot J., et al. Interleukin-18 (interferon-gamma inducing factor) is produced by osteoblasts and acts via granulocyte macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J. Exp. Med. 1997, 185:1005-1012.
263. Ushio S., Namba M., Okura T., et al. Cloning of the cDNA for human IFNγ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J. Immunol. 1996, 156:4274-4279.
264. Vidal-Vanaclocha F., Fantuzzi G., Mendoza L., et al. IL-18 regulates IL-1 beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc. Natl. Acad. Sci. USA 2000, 97:734-739.
265. Walker W., Aste-Amezaga M., Kastelein R.A., et al. IL-18 and CD28 use distinct molecular mechanisms to enhance Nk cell production of IL-12-induced IFN gamma. J. Immunol. 1999, 162:5894-5901.
266. Walter D.M., Wong C.P., DeKruyff R.H., et al. IL-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyper-reactivity. J. Immunol. 2001, 66:6392-6398.
267. Wang S., Miura M., Jung Y.-K., et al. Murine caspase-11, an ICE interacting protease, is essential for the activation of ICE. Cell 1998, 92:501-509.
268. Wang W., Tanaka T., Okamura H., et al. Interleukin-18 enhances the production of interleukin-8 by eosinophils. Eur. J. Immunol. 2001, 31:1010-1016.
269. Wang Z.Y., Gaggero A., Rubartelli A., et al. Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int. J. Caner 2002, 98:873-878.
270. Wei X.Q., Leung B.P., Niedbala W., et al. Altered immune responses and susceptibility to Leishimania major and Staphylococcus aureus infection in IL-18-deficient mice. J. Immunol. 1999, 163:2821-2828.
271. Wei X.Q., Leung B.P., Arthur H.M., et al. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J. Immunol. 2001, 166:517-521.
272. Welch W.C., Morrison R.S., Gross J.L., et al. Morphologic, immunologic, biochemical, and cytogenetic characteristics of the human glioblastoma-derived cell line, SNB-19. In Vitro Cell Dev. Biol. Anim. 1995, 31:610-616.
273. Wild J.S., Sigounas A., Sur N., et al. IFN-γ-inducing factor (IL-18) increases allergic sensitization, serum IgE, TH2 cytokines, and airway eosinophilia in a mouse model of allergic asthm. J. Immunol. 2000, 164:2701-2710.
274. Wildbaum G., Youssef S., Grabie N., Karin N. Neutralizing antibodies to IFN gamma-inducing factor prevent experimental autoimmune encephalomyelitis. J. Immunol. 1998, 161:6368-6374.
275. Wong C.K., Li E.K., Ho C.Y., Lam C.W. Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus. Rheumatology 2000, 37:1078-1081.
276. Wong C.K., Li E.K., Ho C.Y., Lam C.W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and TH2 cytokine (IL-4) concentations in patients with systemic lupus erythematosus. Lupus 2000, 9:589-593.
277. Wyman T.H., Dinarello C.A., Banerjee A., et al. Physiological levels of interleukin-18 stimulate multiple neutrophil functions through p38 MAP kinase activation. J. Leukoc. Biol. 2002, 72:401-409.
278. Xiang Y., Moss B. IL-18 binding and inhibition of interferon, γ induction by human poxvirus-encoded proteins. Proc. Natl. Acad. Sci. USA 1999, 96:11537-11542.
279. Xiang Y., Moss B. Identification of human and mouse homologs of the MC51L-53L-54L family of secreted glycoproteins encoded by the Molluscum contagiosum poxvirus. Virology 1999, 257:297-302.
280. Xiang Y., Moss B. Determination of the functional epitopes of human interleukin-18-binding protein by site-directed mutagenesis. J. Biol. Chem. 2001, 276:17380-17386.
281. Xu X., Sun Y.-L., Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT4 amino-terminal domain. Science 1996, 273:794-797.
282. Xu B., Aoyama K., Yu S., et al. Expression of interleukin-18 in murine contact hypersensitivity. J. Interferon Cytokine Res. 1998, 18:653-659.
283. Xu D., Chan W.L., Leung B.P., et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not TH2 cells. J. Exp. Med. 1998, 188:1485-1492.
284. Xu X., Weinstein M., Li C., Deng C. Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Cell Tissue Res. 1999, 296:33-43.
285. Xu D., Trajkovic V., Hunter D., et al. IL-18 induces the differentiation of TH1 or TH2 cells depending upon cytokine milieu and genetic background. Eur. J. Immunol. 2000, 30:3147-3156.
286. Yamaguchi K., Motegi K., Kurimoto M., Endo Y. Induction of the activity of the histamine-forming enzyme, histidine decarbozylase, in mice by IL-18 and by IL-18 plus IL-12. Inflamm. Res. 2000, 49:513-519.
287. Yamamura M., Kawashima M., Taniai M., et al. Interferon-γ-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001, 44:275-285.
288. Yamanaka K., Hara I., Nagai H., et al. synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model. Cancer Immunol. Immunother. 1999, 48:297-302.
289. Yamanaka K., Tanaka M., Tsutsui H., et al. Skin-specific caspase-1 transgenic mice show cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. J. Immunol. 2000, 165:997-1003.
290. Yamano T., Higashi T., Nouso K., et al. Serum interferon-γ inducing factor/IL-18 levels in primary biliary cirrhosis. Clin. Exp. Immunol. 2000, 122:227-231.
291. Yang J., Zhu H., Murphy T.L., et al. IL-18-stimulated GADD45b required in cytokine-induced, but not TCR-induced, IFN-γ production. Nat. Immunol. 2001, 2:157-164.
292. Yap G.S., Ortmann R., Schevach E., Sher A. A Heritable defect in IL-12 signaling in B10.Q/J mice. II. Effect on acute resistance to Toxoplasma gondii and rescue by IL-18 treatment. J. Immunol. 2001, 166:5720-5725.
293. Yatsiv I., Morganti-Kossmann M.C., Perez D., et al. Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective, effects of IL-18-binding protein after experimental closed head injury. J. Cereb. Blood Flow Metab. 2002, 22:971-978.
294. Yin K.J., Chen S.D., Lee J.M., et al. ATM gene regulates oxygen-glucose deprivation-induced nuclear factor-kappaB DNA-binding activity, and downtream apoptotic cascade in mouse cerebrovascular endothelial cells. Stroke 2002, 33:2471-2477.
295. Yoon J.W., Jun H.S., Santamaria P. Cellular and molecular mechanisms for the initiation, and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 1998, 27:109-122.
296. Yoshimoto T., Takeda K., Tanaka T., et al. IL-12 upregulates IL-18 receptor expression on T cells, TH1 cells, and B cells: Synergism with IL-18 for IFN-γ production. J. Immunol. 1998, 161:3400-3407.
297. Yoshimoto T., Tsutsui H., Tominaga K., et al. IL-18, although anti-allergic when administered with IL-12, stimulates IL-4 and histamie release by basophils. Proc. Natl Acad. Sci. USA 1999, 96:13962-13966.
298. Yoshimoto T., Mizutani H., Tsutsui H., et al. IL-18 induction of IgE: Dependence on CD4+ T cells, IL-4 and STAT6. Nat. Immunol. 2000, 1:132-137.
299. Zaccone P., Phillips J., Conget I., et al. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes 1999, 48:1522-1528.
300. Zepter K., Haffner A., Soohoo L.F., et al. Induction of biologically active IL-1 beta-converting enzyme and mature IL-1 beta in human keratinocytes by inflammatory and immunologic stimuli. J. Immunol. 1997, 159:6203-6208.
301. Zhang T., Kawakami K., Qureshi M.H., et al. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect. Immun. 1997, 65:3594-3599.
302. Zhou X.Y., Wang X., Wang H., et al. Ku affects the ATM-dependent S phase checkpoint following ionizing radiation. Oncogene 2002, 21:6377-6381.